The Japanese pharmaceutical company Astellas Pharma Inc. is the eighth pharmaceutical company to join the Neglected Tropical Diseases Drug Discovery Booster, a global consortium launched in 2015 by DNDi to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease.
Daiichi Sankyo RD Novare and DNDi are pleased to announce the financial support of the Japan Global Health Innovative Technology Fund to their new collaboration on natural products.
DNDi is very pleased to announce the renewed commitment of the Global Health Innovative Technology Fund (GHIT), its donor since 2013, to DNDi projects on leishmaniasis and Chagas disease.
Research Research [26 January, 2017]
The Malaysian Reserve [19 January, 2017]
“Doctors should be more involved in research”
Borneo Post Online [19 January, 2017]
“Health Ministry aims to lower treatment cost for hepatitis C”
The Huffington Post [17 January, 2017]
“This man went abroad and brought back a disease U.S. doctors had never seen”
The Huffington Post [20 December, 2016]
“A parasite attacked this dad’s brain and destroyed his family”
The Huffington Post [13 December, 2016]
“How disease detectives unearthed a forgotten drug to fight a lethal illness”
Toremaga [8 December, 2016]
“スーダン・ハルツーム大学のアーメド ファハル外科教授が来日 重篤な感染症「マイセトーマ(菌腫)」について講演を行う” – “Professor Ahmed Fahal, surgeon from Sudan / Khartoum University will give a lecture on the serious infectious disease: Mycetoma”
The Huffington Post [6 December, 2016]
“18 diseases the world has turned its back on”
Ärzteblatt [1 December, 2016]
“Mehr Geld für die Forschung zu armutsbedingten Erkrankungen” – “More money for research on poverty-related diseases”
The Huffington Post [1 December, 2016]
“This group helps fight devastating diseases the world ignores”
WuXi App Tec [1 December, 2016]
“Harnessing science for the most neglected diseases – A chat with Charles Mowbray, Ph.D., Head of Drug Discovery, DNDi“
KfW, on behalf of the Federal Ministry of Education and Research (BMBF), grants EUR 10 Million to DNDi
DNDi has been awarded EUR 10 million towards the development of treatments against sleeping sickness, visceral leishmaniasis, Chagas disease, and filarial diseases. The grant will be starting this year and be disbursed over five years.